High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model.
about
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility.Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model.Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice.Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy.Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse modelTumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models.Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)Toxicology and efficacy of tumor-targeting Salmonella typhimurium A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice.Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma.A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model.Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Cancer Orthotopic Mouse Model.Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase.Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapIndividualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: Decoy, trap and kill chRegorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 in a patient-derived orthotopic xenograft (PDOX) nude mouse model.Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth.Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.Cell mass-dependent expression of an anticancer protein drug by tumor-targeted Salmonella.Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors.Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
P2860
Q33829258-4B0788B5-5A51-4026-B542-307A29478C34Q33829542-C84FD8E1-7793-404E-BD3D-1769A131F408Q36097450-DA1E069F-DF4F-4116-A1C0-BF3C3CCF4ED0Q36310211-8B34AF68-D6E2-41A3-AD49-F9BBAE9E18A1Q37565198-D4631085-55D9-449D-9F07-BF93DC6877B3Q37665652-087CDFC7-D8CB-4F5A-B265-A4517F6E7CBDQ37687682-8DBAB23D-8366-4C6D-8339-8E406EEFC1CCQ37687695-F3C8EE4F-6D54-427A-992A-9A5DFF6158ACQ37699156-3416FC3D-962A-4A5E-9CF2-A24DF7EFA2A3Q37745932-67CF53F9-EE6E-455F-B4AF-DBD40AC6C208Q39057954-5BD14663-757F-42A2-BA95-CCCF8591083CQ41471129-C2F63755-E3AF-4B3C-9659-0D0DCD88C83EQ41551244-3B36181E-C4EE-404A-B19D-1793D099F013Q41661119-9C1F73B2-C94D-481A-BDFE-3C2B6D9AB019Q42139483-B313747D-03BB-427F-8CB8-7C04628F64EEQ42362667-A663982C-BF1E-4FB4-BAEC-A71938FB901FQ43071116-B3162A5B-B2A7-4537-BBAE-0F3EBDA33BB0Q44144608-1931E012-8E6A-4DBE-A247-B788E1A5445DQ46020823-BCB9B13C-D1A9-423E-B783-C0A00EACE0F9Q46023921-7550C478-905E-49A8-B74D-9DF665DBA201Q46115870-CD756676-CAB3-4C27-B924-6BD92C94D00DQ46142258-E18FD59D-6F95-4C1B-9A12-4121CD992CF0Q46198099-5C6B4A8C-114B-4C42-8F99-781438426978Q46314062-1225CEE2-4F95-4DB2-93F6-3DB337904D5DQ46326758-7DBF89AC-BC48-4281-9B08-7006CB08CC03Q46341637-D39AB249-3BD1-4AAA-8DA8-179F8DFBF8E7Q46416035-E93D8279-8A4D-438A-BE89-58BFC62C30C7Q46417828-40AFB287-BDC4-46C2-AE44-9B51E5AE5590Q46560568-084AF420-C340-409C-89DC-6DFF39909C83Q47105755-BED63128-781E-48F1-AA52-A0B89A77557AQ48135854-EE067509-A1ED-4053-B856-BA9CBA3CA4BDQ48156221-CD6FABB3-7D6C-4532-8F1E-2609C4FAC9DCQ48243511-723B1F84-D2E1-4B94-A7CE-6249FC67C3A0Q48595604-40AB9653-B32E-4381-91EA-26E55FAF635CQ49185022-9EE3BACD-6265-489C-96DA-4FC96FDAA4F0Q50317370-6D40F2F8-8CD0-4819-9BEA-2E0303BBD17AQ50328960-CCC45D3F-A855-4EB5-9B62-9A37047F7740Q50353132-ACC46F60-4098-4552-B34D-B6E172084E1FQ52603159-3F180B1D-D52C-4CF0-BDA5-7C2632C1FB9BQ55076815-FCA3CC26-13CE-4E8D-A54E-842AF8ECC77F
P2860
High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High efficacy of tumor-targeti ...... nograft PDOX nude mouse model.
@en
High efficacy of tumor-targeti ...... nograft PDOX nude mouse model.
@nl
type
label
High efficacy of tumor-targeti ...... nograft PDOX nude mouse model.
@en
High efficacy of tumor-targeti ...... nograft PDOX nude mouse model.
@nl
prefLabel
High efficacy of tumor-targeti ...... nograft PDOX nude mouse model.
@en
High efficacy of tumor-targeti ...... nograft PDOX nude mouse model.
@nl
P2093
P2860
P356
P1433
P1476
High efficacy of tumor-targeti ...... enograft PDOX nude mouse model
@en
P2093
Arun Singh
Fritz C Eilber
Fuminori Kanaya
Kei Kawaguchi
Michael Bouvet
Robert M Hoffman
Tasuku Kiyuna
Yasunori Tome
P2860
P304
33046-33054
P356
10.18632/ONCOTARGET.8848
P407
P577
2016-05-01T00:00:00Z